Clinical trials: Relapsing Remitting Multiple Sclerosis RRMS
- Condition Relapsing Remitting Multiple Sclerosis RRMS
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Relapse Remitting Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes.
- Trial name
- AGNOS (NCT05084638)
- Testing
- Ofatumumab
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis (rrMS)
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).
To evaluate the safety, bio-distribution, and radiation dosimetry; and to optimize the Imaging Protocol of GEH120714 (18F) Injection.
- Trial name
- NCT01738347
- Testing
- Arm 1 - GEH120714 (18F) Injection
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a 3-part study where Parts A, B (single-blind - investigator and subject blind) will enrol healthy volunteers and Part C (open-label) will enrol RRMS patients.
- Trial name
- NCT01808482
- Testing
- Part A: 100 mg/mL GSK2618960, Part B: Dose of GSK2618960 decided from Part A, Part C: Dose of GSK2618960 decided from Part A and B
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and…
- Trial name
- NCT01085318
- Testing
- Rebif
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono
Cognition, Brain Volume Loss
Effect of Fingolimod on Neurodegeneration
This was a 24-month, open-label, multicenter study with a single treatment arm design. Primary objective of this study was: -To investigate the effects of Fingolimod on cognitive performance in highly active relapsing remitting…
- Trial name
- NCT02575365
- Testing
- 0,5 mg Fingolimod
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals